Immunic Reports Q3 2026 Results and Corporate Update

Immunic, Inc., a biotechnology company, announced its Q3 2026 financial results. The company is advancing its Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium, targeting relapsing multiple sclerosis, with data expected in December 2026. They are also preparing for a potential New Drug Application in 2027 if results are positive.

The company reported a significant rise in operating expenses, reaching $43.4 million for Q3, driven by increased R&D and administrative costs. R&D expenses increased by $3.9 million, with significant investments in personnel and drug supply. G&A expenses rose to $19.4 million, mainly due to personnel costs and legal expenses.

As of September 30, 2026, Immunic had $132.0 million in cash, anticipating sufficiency into late 2027. Notably, Immunic expanded its leadership team, appointing new executives to support its regulatory and commercial strategies.